U-16

N/A

Report date: 2025/02/24 16:51:01

Base Information

Drug NameU-16
Drug Alias NameU16U-16
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Renal CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Youkadi Smart Life Technology Co LtdShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A